In this webinar, we delved into the intricacies of analyzing ctDNA and other LBx biomarkers and explored strategies to overcome existing challenges, paving the way for its widespread adoption in clinical settings. Watch the recording now.
Webinar Leaders
House Speaker
Dasha Kaloujskaia
Research Analyst
Beacon
Moderator
Frank Plowden
Account Manager
Beacon
Speak with our team about Beacon Biomarkers & Assays - Lung Cancer
What is Beacon Lung Cancer?
Our inaugural Beacon Biomarkers & Assays offering focuses on lung cancer, covering all biomarkers, assays and clinical trials investigating targeted therapies within the lung cancer landscape.
From preclinical validation of biomarkers and assays to regulatory interactions and updates to clinical trial data, this module encapsulates everything you need to know about the lung cancer biomarker and assay space.
How Beacon Lung Cancer Works
Search the biomarker, assay and trial lung cancer landscape by over 30 unique search filters including:
- Biomarker biology and classification
- Assay platform technology
- Regulatory status
- Drug target and therapeutic class
- Disease stage and line of therapy
Customize your search strategy to give you the data you need for your research focus.
What is Beacon?
Our state-of-the-art assay and comprehensive biomarker landscape provide unparalleled insights into this devastating disease, empowering researchers, translational scientists, and bio-pharma companies to make informed decisions and advance patient care.
Learn more about how our biomarkers, assays, and trials Lung Cancer database solutions can be tailored to your research requirements
